VEGFA and stroke disorder: Edaravone readily crosses the BBB, scavenges multiple radical species including superoxide and under experimental conditions inhibits important pathogenic mechanisms such as delayed neuronal death, microglia-induced neurotoxicity, long-term inflammation, and expression of vascular endothelial growth factor and MMP-9, when given within 12–36 h of stroke onset [58,59,60].